Summary: giant cell tumor of bone Safety and efficacy of denosumab for giant cell tumor of bone – What have we learnt, and where to from here?

Slides:



Advertisements
Similar presentations
1 Collaborations with Dr. PI Terasaki 1.Natural anti-human lymphocyte cytotoxic antibodies in mammalian sera (Ferrone S….., Terasaki PI: i) Transplantation.
Advertisements

P53 The Master Guardian of the Genome. p53 gene mutations in human tumors Greenblatt et al. (1995) Cancer Res. 54: %
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
The Notch-  -Secretase Pathway. Notch activation involves the proteolytic cleavage of the Notch ligand/receptor complex by  -secretase to release the.
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
Cancer Treatment from the DNA Perspective
P53 The Master Guardian. R point Cell cycle control involves several checkpoints and checkpoint (molecular breaking) mechanisms.
BRF Begin with BRAF Searching for a target in metastatic melanoma?
THE PROMISE OF STEM CELL RESEARCH Marisa Bowers Donghong Zhao Karen S. Aboody, M.D. et al. Assistant Professor Divisions of Hematology/HCT & Neurosciences.
MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.
Inhibition of SHH signaling enhances Docetaxel efficacy in castration-resistant prostate cancer cells Sierra L. Lawhorne 1,2, Sakthivel Muniyan 1, Parthasarathy.
PI-103 in Chordoma Joseph Schwab, Cristina Antonescu, John Healey, Patrick Boland, G. Petur Nielsen, Andrew Rosenberg, Edwin Choy, David Harmon, Thomas.
Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy.
Stress Regulation of Tumor Biology Robert T. Croyle, PhD Director Division of Cancer Control and Population Sciences Concept Presentation NCI Board of.
Malignant Melanoma and CDKN2A
Co-supervisor: Prof Richard Lock
12 th Annual CTOS Meeting 2006 SESSION 11 Molecular biology for the patients: Define new targets? Predict Outcome? Moderators: Ole Steen Nielsen & Irene.
Here are some CML slides that may be helpful for your presentation.
A Micro RNA Polymorphism (MiRSNP) in 3’UTR of K-ras gene was associated with clinical outcome in mCRC patients treated with either single agent cetuximab.
© NlH National Center for Image Guided Therapy, 2012 ASNR 2012 Imaging Genomic mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
P53 Missense Mutation Cancer. Outline Disease related to p53 Role and regulation pathway Structure of p53 Missense mutation and consequences Experiment’s.
OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the.
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
CANCER. General A general grouping of all diseases related to unregulated cell growth Cancers generally develop by an accumulation of mutations of the.
GDC-0449 in Patients With Advanced Chondrosarcomas: a French Sarcoma Group / French and US NCI phase II collaborative study Antoine Italiano, Axel Le Cesne,
Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Prostate Cancer – a model of Epigenetic Catastrophe? A Perry et al,, End. Rel. Cancer 2006.
Src signaling is involved in chemoresistance and migration of chondrosarcoma cells Jolieke G. van Oosterwijk¹, Inge H. Briaire- de Bruijn¹, Maayke A.J.H.
TSC1 and Facial Angiofibromas
Insilico design, synthesis and biological evaluation of inhibitors of hypoxia- inducible factor (HIF-1) as antitumor agents Lucía Minini, Maira De Negri,
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
Biomarkers in CRC: Are We Any Closer to Our Goal of Personalized Medicine? Lee M. Ellis, MD Depts. of Surgical Oncology and Cancer Biology U.T. M.D. Anderson.
Bmi-1 in Cancer Cancer genetics 2012/04/ 전종철
1 Trends in drug development programs in the era of Personalized Medicine Gunnar Saeter, M.D., Ph.D. Head, Institute for Cancer Research Oslo University.
Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,
PI3K inhibition does not Effect the BH3 Profile of SW620 Cells
Von Hippel-Lindau Syndrome
Mouse Double Minute 2 (MDM2)
Angiogenesis and hepatocellular carcinoma
Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.
PI3K Pathway Inhibitors
Graduate School of Medical Science & Egineering
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
The Biology Behind BCL2 as a Target in Myeloma
Extracellular Regulation of Apoptosis
UHRF1 is regulated by miR-9 in colorectal cancer
Figure 3 Physiological regulation of autophagy in the heart
PTEN Tumor Suppressor and Cancer
Angiogenesis and hepatocellular carcinoma
Michael S. Dodd et al. BTS 2018;3:
Poster session n. 2.
NOTCH and PI3K-AKT Pathways Intertwined
Tumor Metabolism: MAGE-A Proteins Help TRIM Turn Over AMPK
John D. Gordan, Craig B. Thompson, M. Celeste Simon  Cancer Cell 
Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program
Lan-Hsin Wang, Nicholas E. Baker  Developmental Cell 
Proposed spiral model for prostate cancer progression.
Understanding Apoptotic Mechanisms
Smoothing Out Drug Resistance
Khalid S. Mohammad, Theresa A. Guise  Cancer Cell 
Figure 2 Signalling downstream of the IL-6 receptor
Gramicidin A (GA) decreases HIF protein expression in RCC cells.
Possible outcomes of therapeutic treatments using the spiral model.
The critical roles of miR-23a and miR-27a in colorectal cancer progression. miR-23a primarily increases cell motility through downregulation of its target.
Putative molecular pathways showing how GSK3β regulates the fate of tumor cells (survival, proliferation, or apoptosis) and influences their sensitivity.
HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.
Compartmentalized cellular functions of KDM4A.
No Driver behind the Wheel? Targeting Transcription in Cancer
Presentation transcript:

Summary: giant cell tumor of bone Safety and efficacy of denosumab for giant cell tumor of bone – What have we learnt, and where to from here?

Summary: chondrosarcomas GDC-0449 in patients with advanced chondrosarcomas: a French/US and French National Cancer Institutes Phase II collaborative study (Italiano) Outcomes of inoperable central chondrosarcoma (Picci) SRC signaling is involved in chemoresistance and migration of chondrosarcoma cells (van Oosterwijk)

POSTER: MTORC1 inhibitor targets SRC oncogenic signaling via MIRs in human chondrosarcoma PRP1 (an MTORC1 inhibitor) targets SRC via upregulation of MIR181A/99A/450A/199b5b SRC downregulates these MIRs MIR99A regulates MTOR/FGFR3 Complex feedback loops involving RAS/MAPK and PI3K pathways PRP1 has cytostatic effects Galoian, Temple

Summary: chordoma High-dose single fraction radiotherapy for the management of chordomas of the spine and sacrum (Yamada et al) Germline polymorphisms in brachyury chordoma risk (Flanagan et al) The landscape of mutations in chordoma: PIK3CA and epigenetic modifiers (Campbell)

POSTER: HDAC inhibitor (Panobinostat) effects on mesenchymal tumors and chordomas Panobinostat inhibits growth of chondrosarcoma line JJ012 No effect on chordoma lines Effects independent on effects on ubiquitin ligase pathway Suggest combinations with other agents where resistance exists Galoian, Temple

HIF-1 Signaling in Chordoma is Identical to Nucleus Pulposus and Confers Survival Advantage in Hypoxic Environment John A Abraham, MD 1 Francis J Hornicek MD PhD 2 Irving Shapiro PhD 1 Makarand Risbud PhD 1 1 Rothman Institute at Thomas Jefferson University Philadelphia, PA 2 Massachussetts General Hospital Boston, MA

Hypothesis: – Chordoma is embryologically similar to nucleus pulposus cells – HIF-1 is an important factor in protecting NP cells from apoptosis in the hypoxic conditions in which they reside. – The purpose of this study was to determine if a similar mechanism could be functioning in Chordoma cells. Summary of Findings – Chordoma and NP cells show identical patterns of HIF-1  expression under normoxic and hypoxic conditions, unlike cells derived from most other tissues – Transcription of HIF-1 in both Chordoma and NP increases significantly in hypoxic conditions – Hypoxia protects NP cells from apoptotic stimuli. Serum starvation under hypoxic conditions produces significantly less apoptosis that under normoxic conditions Discussion – HIF-1 is likely a key factor in Chordoma cell survival under hypoxic conditions. – Interruption of HIF-1 signaling may be a therapeutic mechanism HIF-1 Signaling in Chordoma is Identical to Nucleus Pulposus and Confers Survival Advantage in Hypoxic Environment